Сравнительная характеристика результатов применения разнонаправленной интравитреальной фармакотерапии в лечении диабетического макулярного отека

    1. Бикбов М.М., Гильманшин Т.Р., Зайнуллин Р.М., Кудоярова К.И. К вопросу об эпидемиологии сахарного диабета и диабетической ретинопатии в Республике Башкортостан. Acta Biomedica Scientifica. 2019;4(4): 66–69. [Bikbov MM, Gil'manshin TR, Zainullin RM. Epidemiology of diabetic retinopathy in the republic of Bashkortostan. Acta Biomedica Scientifica. 2019;4(4): 66–69 (In Russ.)] doi: 10.29413/ABS.2019-4.4.9

    2. Бикбов М.М., Зайнуллин Р.М., Гильманшин Т.Р., Халимов Т.А. Сравнительный анализ отдаленных результатов хирургического лечения диабетического макулярного отека и эпиретинальной мембраны. Офтальмология. 2019;16(S1): 33–39. [Bikbov MM, Zainullin RM, Gil'manshin TR, Khalimov TA. Сomparative analysis of the long-term results of diabetic macular edema and epiretinal membrane surgical treatment. Oftal'mologiya. 2019;16(S1): 33–39. (In Russ.)]

    3. Bikbov MM, Kazakbaeva GM, Gilmanshin TR, Zainullin RM, et al. Axial length and its associations in a Russian population: the ural eye and medical study. PLoS ONE. 2019;14(2): e0211186.

    4. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91: 1464–1474. doi: 10.1016/s0161-6420(84)34102-1

    5. Трахтенберг Ю.А., Аметов А.С., Демидова Т.Ю., Воробьева И.В. Антиоксидантная терапия непролиферативной диабетической ретинопатии. Врач. 2006;11: 15–18. [Trakhtenberg YA, Ametov AS, Demidova TY, Vorob'eva IV. Antioksidantnaya terapiya neproliferativnoi diabeticheskoi retinopatii. Vrach. 2006;11: 15–18. (In Russ.)]

    6. Haller JA, Schachat AP. Update on the pathophisiology, molecular biology, and treatment of macular edema. Advanced studies in ophthalmology. 2007;4(7): 178–190.

    7. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009;2(59): re1. doi: 10.1126/scisignal.259re1

    8. Исхакова А.Г., Золотарев А.В., Викторов Д.А., Тороповский А.Н., Никитин А.Г. Роль факторов роста сосудов в развитии диабетической ретинопатии и макулярного отека. Российский офтальмологический журнал. 2018;11(2): 62–69. [Iskhakova AG, Zolotarev AV, Viktorov DA, Toropovsky AN, Nikitin AG. The role of vascular growth factors in diabetic retinopathy and macular edema development. Russian ophthalmological journal. 2018;11(2): 62–69 (In Russ.)] doi: 10.21516/2072-0076-2018-11-2-62-69

    9. Ando R, Noda K, Namba S, et al. Aqueous humour levels of placental growth factor in diabetic retinopathy. Acta Ophthalmol. 2014;92: 245–246. doi: 10.1111/ aos.12251

    10. Miyamoto N, de Kozak Y, Jeanny J, et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab retinopathy. Diabetologia. 2007;50: 461–470. doi: 10.1007/s00125-006-0539-2

    11. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular. Angiogenesis. 2012;15(2): 171–185. doi: 10.1007/s10456-011-9249-6

    12. Санторо Э.Ю. Опыт применения афлиберцепта в лечении диабетического макулярного отека по стандартному протоколу в реальной клинической практике. Российский офтальмологический журнал. 2018;11(4): 80–85. [Santoro EYu. Experiences of using aflibercept in diabetic macular edema treatment: data from routine clinical practice. Russian ophthalmological journal. 2018;11(4): 80–85 (In Russ.)] doi: 10.21516/2072-0076-2018-11-4-80-85

    13. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrosio AF, Forrester JV. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48: 5257– 5265.

    14. Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in pathophysiology and treatment. Cell Biosci. 2014;4: 27. doi: 10.1186/2045-3701-4-27.e

    15. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30: 65–84. doi: 10.1007/ s00281-008-0111-x

    16. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59: 1244–1253. doi: 10.2337/db09-1216

    17. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012;12: 364–375. doi: 10.1007/s11892-012-0281-8

    18. Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, Nam DH. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152: 686–694. doi: 10.1016/j. ajo.2011.03.033

    19. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the european society of retina specialists (EURETINA). Ophthalmologica. 2017;237(4): 185–222. doi: 10.1159/000458539

    20. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46: 1440–1444. doi: 10.1167/ iovs.04-0905

    21. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52: 80–86. doi: 10.1167/ iovs.10-5285

    22. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128: 289–296. doi: 10.1001/archophthalmol.2010.21

    23. Kodjikian L. International pharmacological management of diabetic macular edema in real-life observational studies. Biomed Res Int. 2018;8: 8289253. doi: 10.1155/2018/8289253

    24. Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex) in patients with persistent diabetic macular edema. Clin Ophthalmol. 2013;7: 1423–1428. doi: 10.2147/OPTH.S48364

    25. Каменских Т.Г., Батищева Ю.С., Колбенев И.О. и др. Опыт антиангиогенной и кортикостероидной терапии диабетического макулярного отека. Саратовский научно-медицинский журнал. 2017;13(2): 383– 388. [Kamenskikh TG, Batishcheva YuS, Kolbenev IO. Experience of antiangiogenic and corticosteroid therapy of a diabetic macular edema Saratov. Journal of Medical Scientific Research. 2017;13(2): 383–388. (In Russ.)]

    26. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI study: Phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118: 1819–1826. doi: 10.1016/j. ophtha.2011.02.018

    27. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122: 2044–2052. doi: 10.1016/j. ophtha.2015.06.017

    28. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121: 2247–2254. doi: 10.1016/j. ophtha.2014.05.006

    29. Ziemssen F, Schlottman PG, Lim JI, et al. Initiation of intravitreal afliber-cept injection treatment in patients with diabetic macular edema: a review of VIVID DME and VISTA DME data. Int J Retina Vitreous. 2016;2: 16. doi: 10.1186/s40942-016-0041-z

    30. Marco A. Zarbin anti-VEGF agents and the risk of arteriothrombotic events. Asia Pac J Ophthalmol. 2018;1: 63–67. doi: 10.22608/APO.2017495

    31. Martinez AH, Delgado EP, Silva G, et al. Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients? Eur J Ophthalmol. 2019;5: 1–8. doi: 10.1177/1120672119848257

    32. Busch С, Zur D, Fraser-Bell S, Lains I, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetologica. 2018;55: 789–796. doi: 10.1007/s00592-018-1151-x